P. Akt-est-un-complexe-protéique, qui, en activant mTOR (mammalian Target Of Rapamycin) va favoriser la carcinogenèse par une augmentation de la synthèse des protéines nécessaires au développement tumoral Cette voie est située en aval des récepteurs à activité tyrosine kinase (VEGFR par exemple). L'activation d'un RTK induit l'activation de la phosphatidylinositol-3-kinase (PI3K) PI3K est un hétérodimère constitué de deux sous-unités : une sous-unité régulatrice p85 et une sous-unité catalytique p110 (Dreyer C, 2008). PI3K activé va phosphoryler le phosphatidyl-inosiltol-diphosphate (PIP2) en phosphatidyl-inositol-triphosphate (PIP3) ce qui permet l', 2008.

. En-situation-physiologique, phosphatase and tensin homologue deleted on chromosome 10) permet la régulation de cette voie en s'opposant à la phosphorylation de PIP2 par PI3K, ce qui a pour conséquence l'inhibition d'AKT. Une diminution de l'expression de PTEN a été retrouvée dans de nombreux cancers chez l'homme dont le cancer du rein, 2009.

. Ainsi, angiopoïétine 2 pourraient bloquer efficacement l'angiogenèse et par extension, la croissance tumorale. Il est cependant difficile de limiter l'action d'un anticorps sur l'angiopoïétine 2 sans action sur l'angiopoïétine 1 de par la similitude des deux facteurs. L'AMG-386

. Gaviscon®, Il est nécessaire d'espacer la prise de ces médicaments d'au moins deux heures avec la prise de sunitinib (RCP Sutent®)

I. Sur-liste, Sutent® est un médicament soumis à prescription hospitalière. Sa prescription est réservée aux spécialistes en oncologie ou en hématologie ou aux médecins compétents en cancérologie

L. Solubilité-du-sorafénib-est-diminuée-lorsque-le, C'est pourquoi les anti-H2 et les inhibiteurs de la pompe à protons (IPP) peuvent diminuer les concentrations de sorafénib

. Gaviscon®, Il est nécessaire d'espacer la prise de ces médicaments d'au moins deux heures avec la prise de sorafénib

T. Abrams, L. Lee, L. Murray, N. Pryer, and J. Cherrington, SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer, Mol. Cancer Ther, vol.2, issue.5, pp.471-479, 2003.

L. Albiges, S. Oudard, S. Negrier, C. A. Gravis, G. Joly et al., Complete Remission With Tyrosine Kinase Inhibitors in Renal Cell Carcinoma, Journal of Clinical Oncology, vol.30, issue.5, pp.482-489
DOI : 10.1200/JCO.2011.37.2516

J. Assouad, B. Petkova, P. Berna, A. Dujon, C. Foucault et al., Renal Cell Carcinoma Lung Metastases Surgery: Pathologic Findings and Prognostic Factors, The Annals of Thoracic Surgery, vol.84, issue.4, pp.1114-1134, 2007.
DOI : 10.1016/j.athoracsur.2007.04.118

P. Auguste, S. Lemiere, F. Larrieu-lahargue, and A. Bikfalvi, Molecular mechanisms of tumor vascularization, Critical Reviews in Oncology/Hematology, vol.54, issue.1
DOI : 10.1016/j.critrevonc.2004.11.006

N. Azad, E. Posadas, V. Kwitkowski, S. Steinberg, L. Jain et al., Combination Targeted Therapy With Sorafenib and Bevacizumab Results in Enhanced Toxicity and Antitumor Activity, Journal of Clinical Oncology, vol.26, issue.22
DOI : 10.1200/JCO.2007.10.8332

E. Barrascout, J. Medioni, F. Scotte, J. Ayllon, A. Mejean et al., Angiogenesis inhibition: review of the activity of sorafenib, sunitinib and bevacizumab], Bull Cancer, vol.97, pp.29-43, 2010.

A. Bennasroune, A. Gardin, D. Aunis, G. Crémel, and P. Hubert, Tyrosine kinase receptors as attractive targets of cancer therapy, Critical Reviews in Oncology/Hematology, vol.50, issue.1, pp.23-38, 2004.
DOI : 10.1016/j.critrevonc.2003.08.004

P. Bhargava and M. Robinson, Development of Second-Generation VEGFR Tyrosine Kinase Inhibitors: Current Status, Current Oncology Reports, vol.9, issue.2, pp.103-114, 2011.
DOI : 10.1200/JCO.2005.03.6723

C. Boccaccio and P. Comoglio, Invasive growth: a MET-driven genetic programme for cancer and stem cells, Nature Reviews Cancer, vol.16, issue.8, pp.637-682, 2006.
DOI : 10.1038/ncponc0225

E. Calle and R. Kaaks, Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms, Nature Reviews Cancer, vol.91, issue.8, pp.579-91, 2004.
DOI : 10.1002/1097-0215(200002)9999:9999<::AID-IJC1053>3.0.CO;2-T

Y. Cao, L. Wang, D. Nandy, Y. Zhang, A. Basu et al., Neuropilin-1 Upholds Dedifferentiation and Propagation Phenotypes of Renal Cell Carcinoma Cells by Activating Akt and Sonic Hedgehog Axes, Cancer Research, vol.68, issue.21
DOI : 10.1158/0008-5472.CAN-08-2614

O. Casanovas, D. Hicklin, G. Bergers, and D. Hanahan, Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell, pp.299-309, 2005.

D. Cella, J. Li, J. Cappelleri, A. Bushmakin, C. Charbonneau et al., Quality of Life in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib or Interferon Alfa: Results From a Phase III Randomized Trial, Journal of Clinical Oncology, vol.26, issue.22, pp.3763-3772, 2008.
DOI : 10.1200/JCO.2007.13.5145

A. Chase, F. Grand, and N. Cross, Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome. Blood, nov, vol.15110, issue.10, pp.3729-3763, 2007.

K. Chester, B. Pedley, B. Tolner, J. Violet, A. Mayer et al., Engineering Antibodies for Clinical Applications in Cancer, Tumor Biology, vol.25, issue.1-2, pp.91-99, 2004.
DOI : 10.1159/000077727

E. Cho, G. Curhan, S. Hankinson, P. Kantoff, M. Atkins et al., Prospective Evaluation of Analgesic Use and Risk of Renal Cell Cancer, Archives of Internal Medicine, vol.171, issue.16, pp.1487-93, 2011.
DOI : 10.1001/archinternmed.2011.356

W. Chow, G. Gridley, J. Fraumeni, . Jr, and B. Järvholm, Obesity, Hypertension, and the Risk of Kidney Cancer in Men, New England Journal of Medicine, vol.343, issue.18, pp.1305-1316, 20002.
DOI : 10.1056/NEJM200011023431804

B. Corti, N. Zucchini, B. Fabbrizio, G. Martorana, R. Schiavina et al., Pathology and Molecular Pathogenesis of Renal Cell Carcinoma, European Urology Supplements, vol.5, issue.8, pp.573-582, 2006.
DOI : 10.1016/j.eursup.2006.03.005

T. De-reijke, J. Bellmunt, H. Van-poppel, S. Marreaud, and M. Aapro, EORTC-GU group expert opinion on metastatic renal cell cancer, European Journal of Cancer, vol.45, issue.5, pp.765-73, 2009.
DOI : 10.1016/j.ejca.2008.12.010

B. Delahunt, J. Eble, M. Mccredie, P. Bethwaite, J. Stewart et al., Morphologic typing of papillary renal cell carcinoma: Comparison of growth kinetics and patient survival in 66 cases, Human Pathology, vol.32, issue.6
DOI : 10.1053/hupa.2001.24984

C. Dreyer, M. Sablin, S. Faivre, and R. E. , Topics in mTOR pathway and its inhibitors]. Bull Cancer, pp.87-94, 2009.

J. Edeline, C. Vigneau, J. Patard, and N. Rioux-leclercq, Signalling pathways in renal-cell carcinoma: from the molecular biology to the future therapy], Bull Cancer, vol.97, pp.5-15, 2010.
URL : https://hal.archives-ouvertes.fr/inserm-00480057

L. Eklund and B. Olsen, Tie receptors and their angiopoietin ligands are context-dependent regulators of vascular remodeling, Experimental Cell Research, vol.312, issue.5, pp.630-671, 2006.
DOI : 10.1016/j.yexcr.2005.09.002

B. Escudier and V. Kataja, Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Annals of Oncology, vol.72, issue.9, pp.137-139, 2010.
DOI : 10.1200/JCO.2007.13.3223

B. Escudier, T. Eisen, W. Stadler, C. Szczylik, S. Oudard et al., Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma, New England Journal of Medicine, vol.356, issue.2, pp.125-159, 2007.
DOI : 10.1056/NEJMoa060655

B. Escudier, M. Goupil, C. Massard, and K. Fizazi, Sequential therapy in renal cell carcinoma. Cancer, 2009.

B. Escudier, A. Pluzanska, P. Koralewski, A. Ravaud, S. Bracarda et al., Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial, The Lancet, vol.370, issue.9605, pp.2103-2114, 2007.
DOI : 10.1016/S0140-6736(07)61904-7

B. Escudier, C. Szczylik, T. Hutson, T. Demkow, M. Staehler et al., Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma, Journal of Clinical Oncology, vol.27, issue.8, pp.1280-1289, 2009.
DOI : 10.1200/JCO.2008.19.3342

D. Feldman, M. Baum, M. Ginsberg, H. Hassoun, C. Flombaum et al., Phase I Trial of Bevacizumab Plus Escalated Doses of Sunitinib in Patients With Metastatic Renal Cell Carcinoma, Journal of Clinical Oncology, vol.27, issue.9
DOI : 10.1200/JCO.2008.19.0108

N. Ferrara, H. Gerber, and J. Lecouter, The biology of VEGF and its receptors, Nature Medicine, vol.99, issue.21, pp.669-76, 2003.
DOI : 10.1073/pnas.152324099

R. Figlin, P. De-souza, D. Mcdermott, J. Dutcher, A. Berkenblit et al., Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alpha. Cancer, pp.3651-60, 2009.

A. Fléchon, H. Boyle, and S. Négrier, [Management of side effects associated with antiangiogenic treatment in renal cell carcinoma], Bull Cancer, vol.97, pp.73-82, 2010.

K. Foster, A. Prowse, A. Van-den-berg, S. Fleming, M. Hulsbeek et al., Somatic mutations of the von Hippel ??? Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma, Human Molecular Genetics, vol.3, issue.12
DOI : 10.1093/hmg/3.12.2169

M. Gross-goupil and B. Escudier, Targeted therapies: sequential and combined treatments], Bull Cancer, vol.97, pp.65-71, 2010.

S. Gupta and M. Fishman, Progress and contrasts of the development of tivozanib for therapy of kidney cancer, Expert Opinion on Pharmacotherapy, vol.34, issue.10, pp.2915-2937, 2011.
DOI : 10.1358/dof.2009.034.10.1417872

J. Hainsworth, D. Spigel, H. Burris, D. Waterhouse, B. Clark et al., Phase II Trial of Bevacizumab and Everolimus in Patients With Advanced Renal Cell Carcinoma, Journal of Clinical Oncology, vol.28, issue.13, pp.2131-2137, 2010.
DOI : 10.1200/JCO.2009.26.3152

D. Hanahan and R. Weinberg, Hallmarks of Cancer: The Next Generation, Cell, vol.144, issue.5, pp.646-74
DOI : 10.1016/j.cell.2011.02.013

G. Hudes, M. Carducci, P. Tomczak, J. Dutcher, R. Figlin et al., Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma, New England Journal of Medicine, vol.356, issue.22, pp.2271-81, 2007.
DOI : 10.1056/NEJMoa066838

M. Hughson, L. Schmidt, B. Zbar, S. Daugherty, A. Meloni et al., Renal cell carcinoma of endstage renal disease: a histopathologic and molecular genetic study, J. Am. Soc. Nephrol, vol.7, issue.11, pp.2461-2469, 1996.

J. Hunt, O. Van-der-hel, G. Mcmillan, P. Boffetta, and P. Brennan, Renal cell carcinoma in relation to cigarette smoking: Meta-analysis of 24 studies, International Journal of Cancer, vol.128, issue.1, pp.101-109, 2005.
DOI : 10.1093/oxfordjournals.bmb.a011531

T. Hutson, R. Bukowski, C. Cowey, R. Figlin, B. Escudier et al., Sequential use of targeted agents in the treatment of renal cell carcinoma, Critical Reviews in Oncology/Hematology, vol.77, issue.1, pp.48-62, 2011.
DOI : 10.1016/j.critrevonc.2010.07.018

N. Kased, K. Huang, J. Nakamura, A. Sahgal, D. Larson et al., Gamma Knife radiosurgery for brainstem metastases: the UCSF experience, Journal of Neuro-Oncology, vol.46, issue.2, pp.195-205, 2008.
DOI : 10.1016/0360-3016(90)90421-F

S. Khoo, M. Bradley, F. Wong, M. Hedblad, M. Nordenskjöld et al., Birt-Hogg-Dub?? syndrome: mapping of a novel hereditary neoplasia gene to chromosome 17p12-q11.2, Oncogene, vol.20, issue.37, pp.5239-5281, 2001.
DOI : 10.1111/j.1600-0560.1977.tb00920.x

F. Levi, F. Lucchini, E. Negri, L. Vecchia, and C. , Declining mortality from kidney cancer in Europe, Annals of Oncology, vol.15, issue.7, pp.1130-1135, 2004.
DOI : 10.1093/annonc/mdh270

A. Lévy, L. Sauvin, C. Massard, and J. Soria, Everolimus (RAD001) and solid tumours: a 2008 summary]. Bull Cancer, pp.1205-1216, 2008.

S. Loges, M. Mazzone, P. Hohensinner, and P. Carmeliet, Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell, mars, vol.315, issue.3, pp.167-70, 2009.
DOI : 10.1016/j.ccr.2009.02.007

URL : https://doi.org/10.1016/j.ccr.2009.02.007

A. Lopez-beltran, M. Scarpelli, R. Montironi, and Z. Kirkali, 2004 WHO Classification of the Renal Tumors of the Adults, European Urology, vol.49, issue.5, pp.798-805, 2006.
DOI : 10.1016/j.eururo.2005.11.035

S. Marcus, P. Choyke, R. Reiter, G. Jaffe, R. Alexander et al., Regression of Metastatic Renal Cell Carcinoma After Cytoreductive Nephrectomy, The Journal of Urology, vol.150, issue.2, pp.463-469, 1993.
DOI : 10.1016/S0022-5347(17)35514-3

D. Mcdermott, M. Regan, J. Clark, L. Flaherty, G. Weiss et al., Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma, Journal of Clinical Oncology, vol.23, issue.1, pp.133-174, 2005.
DOI : 10.1200/JCO.2005.03.206

R. Motzer, M. Mazumdar, J. Bacik, W. Berg, A. Amsterdam et al., Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell Carcinoma, Journal of Clinical Oncology, vol.17, issue.8, pp.2530-2570, 1999.
DOI : 10.1200/JCO.1999.17.8.2530

R. Motzer, B. Escudier, S. Oudard, T. Hutson, C. Porta et al., Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial, The Lancet, vol.372, issue.9637, pp.449-56, 20089.
DOI : 10.1016/S0140-6736(08)61039-9

R. Motzer, T. Hutson, P. Tomczak, M. Michaelson, R. Bukowski et al., Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma, New England Journal of Medicine, vol.356, issue.2, pp.115-139, 2007.
DOI : 10.1056/NEJMoa065044

R. Motzer, M. Michaelson, B. Redman, G. Hudes, G. Wilding et al., Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma, Journal of Clinical Oncology, vol.24, issue.1, pp.16-24, 2006.
DOI : 10.1200/JCO.2005.02.2574

S. Negrier, B. Escudier, C. Lasset, J. Douillard, J. Savary et al., Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma, New England Journal of Medicine, vol.338, issue.18
DOI : 10.1056/NEJM199804303381805

S. Négrier, G. Gravis, D. Pérol, C. Chevreau, R. Delva et al., Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial, The Lancet Oncology, vol.12, issue.7, pp.673-80, 2011.
DOI : 10.1016/S1470-2045(11)70124-3

S. Oudard and R. Elaidi, Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: Optimizing patient benefit, Cancer Treatment Reviews, vol.38, issue.8
DOI : 10.1016/j.ctrv.2011.12.009

S. Oudard, N. Thiounn, B. Copel, L. Chauvenet, P. Lauraine et al., Résistance à la chimiothérapie dans les cancers du rein et perspectives thérapeutiques, Journal d'urologie, vol.101, issue.3, pp.122-126

Q. Pan, Y. Chanthery, W. Liang, S. Stawicki, J. Mak et al., Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell, pp.53-67, 2007.

J. Park, P. Lin, and R. Weiss, Targeting the PI3K???Akt pathway in kidney cancer, Expert Review of Anticancer Therapy, vol.4, issue.6, pp.863-70, 2007.
DOI : 10.1016/S1535-6108(03)00308-8

P. Patel, P. Senico, R. Curiel, and R. Motzer, Phase I Study Combining Treatment with Temsirolimus and Sunitinib Malate in Patients with Advanced Renal Cell Carcinoma, Clinical Genitourinary Cancer, vol.7, issue.1, pp.24-31, 2009.
DOI : 10.3816/CGC.2009.n.004

S. Richard, von Hippel-Lindau disease: recent advances and therapeutic perspectives, Expert Review of Anticancer Therapy, vol.98, issue.20, pp.215-248, 2003.
DOI : 10.1073/pnas.98.4.1583

S. Richard, C. Ladroue, S. Gad, S. Giraud, and B. Gardie, Genetics and angiogenesis: the example of von Hippel-Lindau disease]. Bull Cancer, pp.170-179, 2007.

B. Rini, B. Escudier, P. Tomczak, A. Kaprin, C. Szczylik et al., Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial, The Lancet, vol.378, issue.9807, pp.1931-1940, 2011.
DOI : 10.1016/S0140-6736(11)61613-9

B. Rini, S. Halabi, J. Rosenberg, W. Stadler, D. Vaena et al., Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206, Journal of Clinical Oncology, vol.26, issue.33, pp.5422-5430, 2008.
DOI : 10.1200/JCO.2008.16.9847

O. Rixe, R. Bukowski, M. Michaelson, G. Wilding, G. Hudes et al., Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study, The Lancet Oncology, vol.8, issue.11, pp.975-84, 2007.
DOI : 10.1016/S1470-2045(07)70285-1

J. Robert, What is a targeted therapy? The view of the biologist], Bull Cancer, vol.94, issue.7, pp.101-110, 2007.

C. Robson, B. Churchill, and W. Anderson, The results of radical nephrectomy for renal cell carcinoma, J

. Urol, 1969 mars, pp.297-301

S. Rosenberg, Progress in human tumour immunology and immunotherapy, Nature. mai, vol.17411, issue.6835, pp.380-384, 2001.

H. Rugo, R. Herbst, G. Liu, J. Park, M. Kies et al., Phase I Trial of the Oral Antiangiogenesis Agent AG-013736 in Patients With Advanced Solid Tumors: Pharmacokinetic and Clinical Results, Journal of Clinical Oncology, vol.23, issue.24, pp.5474-83, 2005.
DOI : 10.1200/JCO.2005.04.192

M. Sablin, S. Negrier, A. Ravaud, S. Oudard, C. Balleyguier et al., Sequential Sorafenib and Sunitinib for Renal Cell Carcinoma, The Journal of Urology, vol.182, issue.1, pp.29-34, 2009.
DOI : 10.1016/j.juro.2009.02.119

G. Hudes, M. Carducci, P. Tomczak, J. Dutcher, R. Figlin et al., Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma Global ACCR Trial, N Engl J Med Eur. Urol, vol.35655, issue.1, pp.2271-81250, 2007.

B. Shuch, L. Rochelle, J. Klatte, T. Riggs, S. Liu et al., Brain metastasis from renal cell carcinoma, Cancer, vol.17, issue.S, pp.1641-1649, 2008.
DOI : 10.4049/jimmunol.176.3.1456

C. Sternberg, I. Davis, J. Mardiak, C. Szczylik, E. Lee et al., Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial, Journal of Clinical Oncology, vol.28, issue.6, pp.1061-1069, 2010.
DOI : 10.1200/JCO.2009.23.9764

D. Strumberg and S. Seeber, Raf Kinase Inhibitors in Oncology, Oncology Research and Treatment, vol.8, issue.2, pp.101-108, 2005.
DOI : 10.1517/eobt.3.2.263.21157

I. Tomlinson, N. Alam, A. Rowan, E. Barclay, E. Jaeger et al., Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer, Nature Genetics, vol.30, issue.4
DOI : 10.1038/ng849

T. Waldmann, S. Dubois, and Y. Tagaya, Contrasting Roles of IL-2 and IL-15 in the Life and Death of Lymphocytes Implications for Immunotherapy, Immunity, vol.14, issue.2, pp.105-115, 2001.
DOI : 10.1016/S1074-7613(09)00091-0

T. Wang and A. Lockhart, Aflibercept in the Treatment of Metastatic Colorectal Cancer, Clinical Medicine Insights: Oncology, vol.6, pp.19-30
DOI : 10.4137/CMO.S7432

J. Yang and R. Childs, Immunotherapy for Renal Cell Cancer, Journal of Clinical Oncology, vol.24, issue.35, pp.5576-83, 2006.
DOI : 10.1200/JCO.2006.08.3774

J. Yang, L. Haworth, R. Sherry, P. Hwu, D. Schwartzentruber et al., A Randomized Trial of Bevacizumab, an Anti???Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer, New England Journal of Medicine, vol.349, issue.5
DOI : 10.1056/NEJMoa021491

Y. Zhu, Y. Horikawa, H. Yang, C. Wood, T. Habuchi et al., BPDE Induced Lymphocytic Chromosome 3p Deletions May Predict Renal Cell Carcinoma Risk, The Journal of Urology, vol.179, issue.6, pp.2416-2437, 2008.
DOI : 10.1016/j.juro.2008.01.092

E. Raymond, Le concept de cible en cancérologie, John Libbey Eurotext et AMGEN, 2008.